复方甲氧那明治疗感染后咳嗽的疗效和安全性分析

Analysis of efficacy and safety of compound methoxyphenamine in the treatment of post-infectious cough

目的探究感染后咳嗽应用复方甲氧那明治疗的效果与安全性。方法 86例感染后咳嗽患者,采用随机信封法分为对照组和观察组,每组43例。对照组患者采用常规治疗,观察组患者在常规治疗基础上采用复方甲氧那明治疗。比较两组患者咳嗽症状评分、临床症状消失时间、治疗效果、不良反应发生情况。结果治疗后,两组患者白天、夜间咳嗽症状评分均低于本组治疗前,且观察组患者均低于对照组,差异具有统计学意义(P<0.05)。观察组患者咳嗽、咳痰、胸闷消失时间均短于对照组,差异具有统计学意义(P<0.05)。观察组患者治疗总有效率为97.7%(42/43),高于对照组的83.7%(36/43),差异具有统计学意义(χ2=4.962, P=0.026<0.05)。两组患者不良反应发生率比较差异无统计学意义(χ2=0.104,P=0.747>0.05)。结论复方甲氧那明应用于感染后咳嗽患者治疗中,既可改善临床症状,又可提高治疗效果,且用药安全性较高,值得临床推广应用。

Objective To discuss the effect and safety of compound methoxyphenamine in the treatment of post-infectious cough.Methods A total of 86 patients with post-infectious cough were divided by envelope method into control group and observation group,with 43 cases in each group.The control group received conventional therapy,and the observation group received compound methoxyphenamine on the basis of conventional therapy.Comparison were made on cough symptom score,disappearance time of clinical symptoms,treatment effect and occurrence of adverse reactions between the two groups.Results After treatment,both groups had lower daytime and nighttime cough symptom score than those before treatment,and the observation group was lower than the control group.Their difference was statistically significant(P<0.05).The observation group had shorter disappearance time of cough,sputum and chest tightness than the control group,and the difference was statistically significant(P<0.05).The observation group had higher total treatment effective rate as 97.7%(42/43)than 83.7%(36/43)in the control group,and the difference was statistically significant(χ^2=4.962,P=0.026<0.05).Both groups had no statistically significant difference in incidence of adverse reactions(χ^2=0.104,P=0.747 >0.05).Conclusion Application of compound methoxyphenamine in patients with post-infectious cough,can not only improve the clinical symptoms,but also improve the treatment effect with high medication safety.It is worthy of clinical promotion and application.